This website contains information intended solely for healthcare professionals. It is not meant for patients or the general public and should never replace professional medical advice, diagnosis, or treatment. Patients should not rely on this content for decisions about their health or medical care. If you are a patient and have questions about a CooperSurgical Genomics test or its implications, please contact your healthcare provider. Your provider can explain the benefits, risks, and limitations of the test and help determine whether it is appropriate for you.
PGT-A
Unique innovation to help improve the odds of pregnancy and IVF success
The only test using artificial intelligence (AI) based on clinical outcome data, eliminating subjectivity, and improving accuracy.
Using our PGTai platform, we employ two independent analyses (CNV and
SNP) to check for abnormalities, providing greater confidence and ensuring a
high level of accuracy.
Availability
This service is available for sale in selected countries around the world.
>13% increase in ongoing pregnancy and live birth rates vs standard PGT-Aยน
Emerging Evidence
Patientsโ chances of having a baby improved with the PGTaiSM Platform. A single-center study shows the innovative PGTai platform helped patients fulfill their ultimate dream of having a baby by increasing ongoing pregnancy and live birth rates.
Introducing PGT-A with PTA
We have implemented Primary Template-directed Amplification (PTA), a novel approach to DNA amplification for embryo biopsy samples.
This innovation represents the first major advancement to DNA amplification since 2009 and marks a milestone in improving the quality of DNA amplification in embryo samples.
This change is being implemented because CooperSurgical Genomics hopes to provide the most advanced technology available to you and your patients which means from time-to-time upgrades to our technology require that we permanently discontinue outdated processes.
If you have any queries or would like any further information please click here to contact your Territory Account Manager or Clinical Support Specialist.
FAQs
There are no required changes to your clinical processes.
No, there is no added cost to PGT-A testing.
No, at this time we do not anticipate any changes to our key performance metrics.
No, there will not be any changes to the report format or delivery.
No, only samples received after February 19th 2024, will be processed by PTA
There will be a grace period of 90 days (up to May 20th 2024) to submit buccal swabs and documentation related to any PGT-A cases that were analyzed between the dates of Dec 1st 2021 and Feb 19th 2024. During this period our laboratory staff will be happy to conduct retrospective PGT-Complete.
YES! Once we have transitioned to the new processes any cases received after Feb 19th 2024 will have the option of conducting PGT-Complete retrospectively.
Remember, PGT-A cases submitted between Dec 1st 2021 and Feb 19th 2024 will NO longer be eligible for retrospective PGT-Complete after May 20th 2024.
We transitioned amplification for PGT-M cases to PTA starting in Feb of 2023. Only older cases, or those otherwise amplified by a different technology are impacted.
We are providing a 6-month period (until Aug 20th 2024) for our partners to finalize analysis of any embryos held in storage at our CooperGenomicsยฎ locations.
NIPGT-A Research Update
Our dedication to investigation and innovation expands to non-invasive methodologies
Our Overview of the Paper:
1000 Mosaic Embryo Transfers Viotti et al, 2021
Clinic Testimonials
At Care Fertility, we have been impressed with the transition from standard to PGTai; the staff education and clarity of reporting. In addition, we are reassured by the increased precision of this test and believe it brings benefits for our patients.
Alison Campbell
Chief Scientific Officer, Care Fertility Group, London, UK
The switch to PGTai has more than halved the turnaround time on our results, with the lab now averaging 3 days from sample receipt to providing us with the final report. Thatโs been an enormous benefit: those extra few days waiting for results make a huge difference to our patients! Weโve seen a drop in the number of โno callโ results since the changeover to below 2%. Most importantly the level of service from the staff we deal with in the UK laboratory has been outstanding, always friendly, helpful and on top of anything we need.
Kelli Sorby
Scientific Director, Number1 Fertility, Melbourne, Australia
Brochures, Catalogs & Flyers
Reproductive Genetic Testing Brochure
Reproductive Genetic Testing Brochure
PGT-Complete Brochure
PGT-Complete Brochure
PGT-A Patient Brochure
PGT-A Patient Brochure
PGT-A Clinician Brochure
PGT-A Clinician Brochure
PGTai White Paper
PGTai White Paper
1. Buldo-Licciardi J, Large M, McCulloh D, McCaffrey C, Grifo J. Second generation artificial intelligence technology for preimplantation genetic testing (PRT) improves pregnancy outcomes in single thawed euploid embryo transfer cycles (STEET). Presented at American Society for Reproductive Medicine on October 19, 2020.
Available at: https://asrm.confex.com/asrm/2020/meetingapp.cgi/Paper/8645. Accessed November 2, 2021. 2. CooperGenomics, internal data on file.
PGT A (Preimplantation Genetic Testing for Aneuploidy) is a genetic test intended only as a screening tool and is designed to identify whether an embryo has the expected number of chromosomes. It is not a diagnostic test, it cannot detect every chromosome abnormality or genetic abnormality, and it cannot determine whether an embryo will implant, result in a successful pregnancy, or lead to the birth of a healthy child. Healthcare providers should review the testโs indications, limitations, and potential risks and discuss these with their patients to determine whether the test is appropriate for the patientโs individual circumstances. CooperSurgical’s PGT-A test includes a Genetic PN (pronuclei) Check, which is an additional genetic analysis that helps support evaluation of whether fertilization occurred in a typical manner. This test is intended to provide supportive information only and does not confirm embryo viability, health, or likelihood of pregnancy. Both PGT-A and Genetic PN (pronuclei) Check have technical and biological limitations. Genetic testing cannot guarantee pregnancy or the birth of a healthy child.
Get In Touch With Us
We’d love to hear from you. How can we help?